Oil prices rise on talk of Russia sanctions; bouncing off recent lows
On Tuesday, RBC Capital analysts increased the price target for Perspective Therapeutics Inc (NYSE: CATX) to $16 from $15, while maintaining an Outperform rating. According to InvestingPro data, analyst targets for CATX range from $6 to $20.50, with a strong buy consensus. The adjustment comes after recent data updates from the company’s NET program presented at the American Society of Clinical Oncology (ASCO).
The analysts noted that the NET program data demonstrates a competitive objective response rate (ORR) of up to 57%, maintaining best-in-class safety compared to competitors, despite the small sample size. They believe that the program’s profile can be sustained in the second half of 2025, potentially impacting the stock’s performance.
In addition to the NET program, the analysts highlighted the early-stage melanoma program. They indicated potential for this program to provide significant opportunities by 2026, based on preclinical data and its potential synergy with immuno-oncology treatments.
RBC Capital also emphasized the company’s strong cash position, which is expected to support upcoming catalysts. InvestingPro analysis confirms this view, showing the company holds more cash than debt and maintains a healthy current ratio of 17.02x, though it is currently burning through cash rapidly. The analysts believe Perspective Therapeutics’ approach could be applicable across various tumor types, reinforcing their positive outlook.
The decision to adjust the price target reflects updates to the analysts’ model, taking into account the emerging competitive profile of the VMT-α-NET and the optionality in melanoma with VMT01. With the stock currently trading at $2.39, significantly below its 52-week high of $16.55, investors seeking detailed analysis can access comprehensive financial health metrics and additional ProTips through InvestingPro’s exclusive research reports.
In other recent news, Perspective Therapeutics Inc. disclosed key outcomes from its 2025 Annual Meeting of Stockholders, where five board members were elected, and WithumSmith+Brown, PC was ratified as the independent auditor for 2025. The company also received shareholder approval for executive compensation practices. Meanwhile, Oppenheimer adjusted its price target for Perspective Therapeutics to $15 from $16, maintaining an Outperform rating, following the company’s first-quarter results and ongoing clinical programs. Truist Securities also revised its price target to $10 from $21, sustaining a Buy rating, citing changes in commercialization timelines for Perspective’s clinical programs. Perspective Therapeutics concluded the first quarter with $212 million in cash, expected to fund operations into late 2026. Scotiabank (TSX:BNS) initiated coverage with a Sector Outperform rating and a $15 price target, noting the company’s potential in its melanoma, FAP-alpha, and pre-targeting platform programs. The bank highlighted Perspective Therapeutics as one of the few independent players in the radiopharmaceutical industry. These developments reflect varying analyst perspectives on the company’s future performance and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.